Orders from 465 AED Free delivery from 965 AED Ready for pickup dead drop: collect in 5 min

Substances · Cathinone derivatives

N-Ethylhexedrone (Hexen)

C14H21NO CAS 802857-66-5 Analytical reference material — not for human consumption
Preferred name
N-Ethylhexedrone (Hexen)
IUPAC name
2-(ethylamino)-1-phenylhexan-1-one
Parent CAS number (reference)
802857-66-5
Molecular formula
C14H21NO
Molecular weight
219.32 g/mol
InChIKey
CWNKMHIETKEBCA-UHFFFAOYSA-N
PubChem
CID 134822125
Source
PubChem
Verified synonyms & catalog abbreviations
N-Ethylhexedrone Hexen NEH Ethyl-Hexedrone

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

N-Ethylhexedrone (Hexen / NEH)

Stimulant (High-Potency Selective NDRI) Substituted cathinone (N-ethyl hexanophenone)
Verified PubChem & CAS Identity C14H21NO · CAS 802857-66-5 · CID 134822125
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 219.33 g/mol
Peer-Reviewed & Agency Citations 4 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

Potent, selective norepinephrine-dopamine reuptake inhibitor (NDRI) without monoamine-releasing activity. Extending the alpha-side chain by one carbon over NEP increases dopamine uptake blockade >3.5-fold: in HEK293 assays (Eshleman et al., 2019), hDAT IC50 = 46.7 ± 4.0 nM (Ki = 171 ± 38 nM) and hNET IC50 = 97.8 ± 8.3 nM (Ki = 1,259 ± 43 nM), with ~100-fold weaker serotonin inhibition (hSERT IC50 = 4,880 ± 470 nM, Ki = 11,400 ± 1,800 nM). Also exhibits moderate local anesthetic activity and elevated in vitro cytotoxicity in SH-SY5Y neuronal cells.

Biotransformation & Active Metabolites

WHO 42nd ECDD reports mucosal onset within ~2 minutes (peaking at 20–25 minutes) and oral onset at 20–25 minutes (peaking at 50–60 minutes); formal human elimination half-life is unverified.

Temporal Pharmacokinetics

Sharp, hard-hitting dopaminergic rush with moderate local numbing, rapid thought acceleration, ego inflation, and prominent cardiovascular and vasoconstrictive load.

  1. Onset 20–25 minutes oral (2–8 minutes mucosal)
  2. Peak Window 50–60 minutes oral (20–90 minutes mucosal)
  3. Total Window 3–6 hours oral (2–5 hours mucosal)
  4. Residual / Half-Life 1–8 hours (longer after repeated exposure) of persistent tachycardia, cold extremities, anxiety, and insomnia; human plasma half-life is unverified.

Steep response curve: above 30–40 mg mucosal or 40–50 mg orally, mood elevation is rapidly overtaken by persistent tachycardia, cold hands/feet, and anxiety. Hexen is notorious for a brief 30–60 minute mood-elevating rush followed by up to 8 hours of lingering peripheral adrenergic stimulation—making repeated exposure binges rapidly toxic and exhausting.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
5–15 mg oral (5 mg mucosal)
Cognitive & Sensory

Crisp mental awakening, subtle focus enhancement, and mild alertness.

Somatic & Autonomic

Slight heart-rate increase and mild mouth/nasal numbing if mucosal.

Light
15–25 mg oral (PsychonautWiki 5–24 mg / TripSit 15–30 mg mucosal)
Cognitive & Sensory

Functional concentration, heightened motivation, talkativeness, and clean mood lift.

Somatic & Autonomic

Noticeable pulse increase, appetite suppression, dry mouth, and light sweating.

Common Reference
25–40 mg oral (24–30 mg PW / 30–40 mg TripSit mucosal)
Cognitive & Sensory

Strong mood-elevating rush, ego inflation, music immersion, disinhibition, and fierce urge to redose as the rush ebbs.

Somatic & Autonomic

Pronounced and prolonged tachycardia, elevated blood pressure, cold hands and feet (vasoconstriction), and nasal mucosal irritation.

Strong
40–50 mg oral (30–40 mg PW / 40–50 mg TripSit mucosal)
Cognitive & Sensory

Scattered hyper-stimulation, impaired concentration, jittery restlessness, anxiety, and compulsive repeated exposure.

Somatic & Autonomic

Heavy palpitations, chest tightness, bruxism, nausea, tremors, and temporary erectile dysfunction.

Heavy / Toxic Zone
50+ mg oral (40–50+ mg mucosal)
Cognitive & Sensory

Acute panic, auditory distortions/hallucinations, paranoia, and binge-induced stimulant psychosis.

Somatic & Autonomic

Severe hypertension, dangerous arrhythmias, peripheral vasospasm, hyperthermia, and seizures.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

High-affinity dopamine/norepinephrine reuptake blockade paired with MAO inhibition causes fatal hypertensive crisis and arrhythmias.

Cocaine, NEP, Pyrovalerones (alpha-PVP, alpha-PHP, MDPHP), and 25x-NBOMe / 25x-NBOH

Additive NDRI cardiac load and severe vasoconstriction create acute risk of myocardial ischemia, stroke, and seizures.

Tramadol

Markedly lowers seizure threshold alongside intense adrenergic stimulation.

Elevated Hazard — Avoid

MDMA, 4-MMC, 3-MMC, and Amphetamines

Exacerbates Hexen's notoriously prolonged heart-rate elevation, hyperthermia, and neurotoxicity.

Alcohol, Synthetic Cannabinoids, and GHB/GBL

Masks depressant intoxication, worsens dehydration and cardiovascular stress, and has been co-detected in severe forensic poisonings.

Caution / Receptor Attenuation

Cannabis

Strongly amplifies resting tachycardia, chest anxiety, and paranoid thought loops during Hexen's long adrenergic tail.

Caffeine or Nicotine

Worsens vasoconstriction (cold extremities) and jittery palpitations.

Structural Isomer & Sibling Comparison

Hexen (NEH) is ~3.5-fold more potent at blocking DAT than NEP (hDAT IC50 46.7 nM vs. 165 nM), delivering a sharper, more rush-driven peak with moderate local numbing, but at the cost of stronger vasoconstriction, more persistent heart-rate elevation, and a rougher comedown than NEP. Compared to alpha-PHP (its pyrrolidino analogue), Hexen requires roughly twice the milligram amount (common 25–40 mg vs. 10–25 mg).

Physicochemical Stability & Storage

Form: Fine white to off-white crystalline powder or needles as the hydrochloride salt, producing moderate topical mouth/nasal numbing and mucosal irritation. · Soluble in water, ethanol, methanol, DMF, and DMSO.

Store sealed, dry, and protected from light and heat.

Cross-Tolerance & Dependence Profile

Rapid acute tolerance to mood elevation within 2–3 doses; full cross-tolerance with NEP, cocaine, pyrovalerones, and amphetamines (3–7 days to halve, 1–2 weeks to baseline). High psychological addiction liability driven by compulsive binge repeated exposure.

Comprehensive Analytical & Toxicological Monograph

N-Ethylhexedrone (Hexen / NEH; 2-(ethylamino)-1-phenylhexan-1-one; freebase CAS 802857-66-5, hydrochloride CAS 18410-62-3, PubChem CID 134822125) is a six-carbon N-ethylated cathinone queued in weekly synthesis slot #12 as pure analytical powder or crystalline solid (C14H21NO, 219.33 g/mol). Structurally differing from NEP by one additional methylene carbon and from alpha-PHP by replacing the pyrrolidine ring with an N-ethyl amine, Hexen acts in human HEK293 assays as a potent, selective norepinephrine-dopamine reuptake inhibitor (hDAT IC50 = 46.7 nM, hNET IC50 = 97.8 nM) with ~100-fold weaker serotonin transporter inhibition (hSERT IC50 = 4,880 nM) and moderate local anesthetic activity. Precision milligram measurement is essential: TripSit and PsychonautWiki brackets place oral threshold at 5–15 mg, light functional stimulation at 15–25 mg, common mood-elevating stimulation at 25–40 mg, strong intensity at 40–50 mg, and heavy overdose territory above 50 mg (mucosal common range is 24–40 mg, with heavy risk above 40–50 mg). WHO ECDD reviews note mucosal onset within ~2 minutes (peaking at 20–25 minutes over 2–5 hours) and oral onset at 20–25 minutes (peaking at 50–60 minutes over 3–6 hours). Because the initial dopaminergic rush fades much faster than its 1–8 hour noradrenergic tail, compulsive repeated exposure rapidly stacks severe tachycardia, cold extremities from vasoconstriction, and insomnia. Compared to NEP, Hexen hits harder and faster with topical numbing, but imposes heavier cardiac strain; compared to alpha-PHP, it requires roughly double the milligram amount. Never mix Hexen with MAOIs, cocaine, NEP, pyrovalerones, tramadol, MDMA, or 25x-NBOMe.

Chemical Architecture & Structural Profile

N-Ethylhexedrone (Hexen) (2-(ethylamino)-1-phenylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C14H21NO and a molar mass of 219.32 g/mol. The parent molecule is indexed under CAS registry number 802857-66-5 and in the NCBI PubChem database as CID 134822125 (Standard InChIKey: CWNKMHIETKEBCA-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), N-Ethylhexedrone (Hexen) is indexed within the Cathinone structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): moderately addictive with a high potential for abuse. Documented cross-tolerance class: norepinephrine|noradrenergic, dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)